PE 22-28 a fast‑acting antidepressant?

Posted by grace_sleepnerd in Research & News - 3 points, 4 comments.

I just saw a paper on the spadin‑derived PE 22‑28. It’s still preclinical, but the data show a rapid, SSR‑like antidepressant effect in mice after just a single dose. For me, the claim feels a bit over‑hyped yet.

The idea of blocking TREK‑1 to boost serotonin and fast neurogenesis is cool, but no human data yet and no safety profile. I’ve been chasing other mood‑stabilizers and nootropics, and I’m wary of hype. The description says it works faster than an SS:l in animals which looks great if it translates.

I wonder if the community sees that as a plausible early‑stage candidate or just a nice curiosity. Do y’all think a clinical trial is realistic soon, or is this still a lab‑bench concept?

Comments

• greg208: Not gonna lie I’m a bit wary too – the TREK‑1 blockade sounds neat but the leap from a single mouse dose to a human drug is huge. I’ve seen other fast‑acting compounds like ketamine get clinical paths fast because they hit a clear target and have a known safety window, and PE 22‑28 is still a bit of a cocktail out of the lab. From what I get the next step would be a toxicity study in rats before anyone thinks about Phase‑I in people. So for now I’d treat it as a promising curiosity rather than
• liam_sleepnerd: I’m axed on the same note, Greg, toxicology in rats is the next mandatory step. No PK data yet, and I’d want to see plasma half‑life and CNS penetration before flirting with human doses. Anyone know if any labs have begun those studies?
• grace_sleepnerd: Thanks for that, liam. I agree the PK & toxicity are the next big gaps. I’ve seen the paper mention some rat liver microsomes in vitro but no full bioassays yet. Do you know if any team is doing a full PK in rodents Chil? I'd love to see that data before any human talk.
• grace_sleepnerd: Thanks for the perspective, greg. I agree the jump from a single mouse dose to a human is huge, and the lack of a rat toxicity paper is a deal‑breaker. I’m curious if anyone knows of an academic group that’s already doing those studies, maybe the lab that published the original PE 22‑28 paper? If not, I’ll keep an eye out for a preclinical toxicity report before I even think about a trial.

Community discussion - research and educational context only. Not medical advice.